ClinicalTrials.gg
TerminatedNCT02340156Updated Mar 3, 2021Results posted

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

A Phase 2 interventional study of SGT-53 and Temozolomide in RECURRENT GLIOBLASTOMA, sponsored by SynerGene Therapeutics, Inc.. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by SynerGene Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
212th of 221
1 · median 41
Started
2014
with 9 others
Phase 2
99 of 232
13 open now
Registered
143rd of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 212th largest by enrollment of the 221 interventional ones that give a count, is one of 10 that started in 2014, is one of 99 in phase 2, and was the 143rd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this trial is to assess 6 month progression free survival (PFS), overall survival (OS), anti-tumor activity, safety and possibly to evaluate, nanoparticle delivery to tumor site, and the induction of apoptosis in the tumor..

Read the detailed description

The p53 is a vital human tumor suppressor gene. Loss of p53 suppressor function is present in the majority of human cancers. The p53 protein has a diverse range of functions including regulation of cell cycle checkpoints, cell death (apoptosis), senescence, DNA repair, maintenance of genomic integrity, and control of angiogenesis. Abnormalities of the p53 gene may impact the efficacy of standard anticancer treatments such as radiation and chemotherapy. P53 mutation and pathway dysfunction are associated with poor clinical outcomes and the presence of the p53 mutation correlates with resistance to chemotherapy and radiation. The development of somatic gene therapy has created the potential to restore wild type function of p53. SGT-53 is a complex of cationic liposome encapsulating a normal human wild type p53 DNA sequence in a plasmid backbone. This complex has been shown to efficiently and specifically deliver the p53 cDNA to the tumor cells and to cross the blood-brain barrier. Introduction of the p53 cDNA sequence is expected to restore wtp53 function in the apoptotic pathway. P53 restoration has been shown most effective in enhancing cytotoxicity in combination with an agent which results in DNA damage or initiates apoptosis. The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT), which repairs the TMZ-induced DNA lesion by removing the o6-guanine adducts. Thus, a means to down modulate MGMT activity would enhance the therapeutic effect of TMZ. A number of reports have indicated that increasing wtp53 expression can down-regulate expression of DNA repair genes such as MGMT and increases the sensitivity of tumor cells to alkylating agents. This is a Phase II clinical trial of the tumor-targeted SGT-53 nanocomplex in combination with chemotherapeutic agent, temozolomide which is the standard of care for Glioblastoma Multiforme (GBM) brain tumors. We propose to test the combination of SGT-53 and standard temozolomide to determine efficacy and safety in patients with confirmed glioblastoma who have proven tumor recurrence or progression.

03

Conditions studied

  • RECURRENT GLIOBLASTOMA

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed glioblastoma or gliosarcoma in 1st, 2nd or 3rd relapse.
  • Radiographic demonstration of disease progression following prior therapy
  • on MRI performed within 14 days prior to registration.
  • Male or female patients ≥ 18 years of age.
  • Recurrent disease with an:

    • interval of ≥ 3 months following radiotherapy + TMZ;
    • interval of ≥ 14 days between end of surgery and start of protocol therapy for patients who have undergone surgery for recurrent disease.
  • Patients who tolerated previous administration with TMZ
  • Recovery from the effects of prior therapy:

    • 4 weeks from cytotoxic agents
    • 6 weeks from nitrosoureas
    • 4 weeks from any agent
    • 1 week from non-cytotoxic agents
    • 12 weeks from radiotherapy
  • performance status ≥ 60%.
  • Complete blood count/differential at screening with adequate bone marrow function
  • If patient is receiving , must be on stable or decreasing steroid dose within 5 days prior to treatment initiation with SGT-53.
  • Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study.
  • Women of must have a negative serum beta-HCG pregnancy test documented within 3 days prior to study initiation.
  • Women of childbearing potential must agree to use two reliable methods of from screening and up to 30 days after discontinuation of study treatment
  • Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment
  • Acceptable liver function
  • Acceptable blood sugar control
  • Urinalysis: No abnormalities.
  • PT and ≤ 1.5 X
  • Have recovered from any previous therapy side effects or toxicities
  • Organ function characterized by ≤ Grade 1

Exclusion criteria

Exclusion Criteria:

  • Histology other than astrocytoma grade IV
  • Tumor foci detected below the tentorium or beyond the cranial vault.
  • Glioblastoma or gliosarcoma disease with .
  • Patients with a history of any other cancer, unless in complete remission, and off all therapy for that disease for a minimum of 5 years
  • Patients with serum , alanine aminotransferase > 2.5 X the (ULN) and >1.5 ULN
  • Moderate to severe hepatic impairment.
  • Positive results from serology testing, if any available.
  • Supine systolic blood pressure \< 100 mmHg or supine diastolic blood pressure \< 50 mmHg at screening and baseline
  • Renal insufficiency or serum creatinine >1.5 X ULN at screening.
  • Females who are pregnant or lactating or plan to become pregnant during the course of this study.
  • Substance or alcohol abuse or dependence, within 12 months prior to screening.
  • Prior chemotherapy for recurrent GBM with nitrosourea compounds including Gliadel® wafers or bevacizumab.
  • Prior focal radiotherapy within 3 months of screening.
  • Planned treatment, or treatment with any drug within 4 weeks prior to screening.
  • Severe, active co-morbidity
  • Patients who are currently taking Coumadin or Coumadin derivatives other than to maintain patency of venous access lines.
  • Requiring renal dialysis
  • Receiving hematopoietic growth factors
  • Have significant baseline neuropathies
  • Had prior exposure to gene vector delivery products within 6 months
  • Any condition that prevents compliance with the protocol or adherence to therapy.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  • Treated with antibiotics for infection within one week prior to study entry.
  • Fever (> 38.1°C)
  • Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication.
  • Serious nonmalignant disease
  • Enrollment in a concomitant clinical study
  • Have a history of reaction to any of the components of Temozolomide
  • Have a history of hypersensitivity to dacarbazine (DTIC)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    SGT-53 with Temozolomide

    SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.

    Genetic: SGT-53 · Drug: Temozolomide

Interventions

  • GeneticSGT-53

    SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.

  • TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.

    Also known as: Temodar

06

What researchers measure

Primary outcomes

  1. Tumor Response

    The 6 month progression-free survival (PFS) was evaluated using RANO Response Criteria.

    Time frame: 6 months

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    The safety of the combination of SGT-53 and Temozolomide was assessed by analysis of adverse experiences, clinical laboratory tests and physical examinations.

    Time frame: Study drug initiation through 30 days after the last dose of study drug or EOS, whichever is later, approximately 90 days.

  2. Progression-free Survival (PFS)

    Progression-free survival is defined as the time from the date of enrollment to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurs earlier. Subjects who do not have disease progression or have not died will be censored at the date of the last tumor assessment on or prior to the clinical cutoff.

    Time frame: From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  3. Overall Survival (OS)

    Overall survival is defined as the time from the date of enrollment to the date of death from all causes.

    Time frame: From date of registration until the date of death from any cause, assessed up to 180 months.

  4. Anti-tumor Activity

    The anti-tumor activity of the combination of SGT-53 and Temozolomide was determined based upon the RANO criteria.

    Time frame: From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  5. Induction of Apoptosis

    Flow cytometry or histological examination was used to determine the level of apoptosis induced by SGT-53 in tumors resected 3 days after the first SGT-53 infusion (optional procedure)

    Time frame: 3 days

  6. Nanoparticle Tumor Delivery

    As an indicator of nanoparticle delivery to the tumors, DNA PCR was used to determine the presence of SGT-53 delivered exogenous wt p53 in the tumors. This analysis will be performed on any tumors resected 3 days after the first SGT-53 infusion (optional procedure)

    Time frame: 3 days

07

Results

Posted Mar 3, 2021
Limitations and caveats
The number of participant was too small for statistical analysis. The study was terminated.

Participant flow

Recruitment was opened in Houston, Texas, USA and Taichung, Taiwan.

Participant flow — Overall Study
MilestoneSGT-53 With Temozolomide
Started1
Completed1
Not completed0

Outcome measures

PrimaryTumor Response

The 6 month progression-free survival (PFS) was evaluated using RANO Response Criteria.

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryIncidence of Treatment-Emergent Adverse Events

The safety of the combination of SGT-53 and Temozolomide was assessed by analysis of adverse experiences, clinical laboratory tests and physical examinations.

Time frame:
Study drug initiation through 30 days after the last dose of study drug or EOS, whichever is later, approximately 90 days.
Reported as:
Number · Participants
Incidence of Treatment-Emergent Adverse Events
ParticipantsSGT-53 With Temozolomide
Seizure1
Electrocardiogram QT corrected interval prolonged1
Skin ulceration1
SecondaryProgression-free Survival (PFS)

Progression-free survival is defined as the time from the date of enrollment to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurs earlier. Subjects who do not have disease progression or have not died will be censored at the date of the last tumor assessment on or prior to the clinical cutoff.

Time frame:
From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of enrollment to the date of death from all causes.

Time frame:
From date of registration until the date of death from any cause, assessed up to 180 months.

No measurements were reported for this outcome.

SecondaryAnti-tumor Activity

The anti-tumor activity of the combination of SGT-53 and Temozolomide was determined based upon the RANO criteria.

Time frame:
From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

No measurements were reported for this outcome.

SecondaryInduction of Apoptosis

Flow cytometry or histological examination was used to determine the level of apoptosis induced by SGT-53 in tumors resected 3 days after the first SGT-53 infusion (optional procedure)

Time frame:
3 days

No measurements were reported for this outcome.

SecondaryNanoparticle Tumor Delivery

As an indicator of nanoparticle delivery to the tumors, DNA PCR was used to determine the presence of SGT-53 delivered exogenous wt p53 in the tumors. This analysis will be performed on any tumors resected 3 days after the first SGT-53 infusion (optional procedure)

Time frame:
3 days

No measurements were reported for this outcome.

Adverse events

Collected over Study drug initiation through 30 days after the last dose of study drug or End of Study, whichever is later, approximately 90 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SGT-53 With Temozolomide0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventSGT-53 With Temozolomide
SeizureNervous system disorders1/1
Most frequent other events
Most frequent other events
EventSGT-53 With Temozolomide
Electrocardiogram QT corrected interval prolongedInvestigations1/1
Skin ulcerationSkin and subcutaneous tissue disorders1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SGT-53 With Temozolomide
<=18 years0
Between 18 and 65 years1
>=65 years0
Age, Continuous
Age, Continuous(years)SGT-53 With Temozolomide
Median60 (60 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)SGT-53 With Temozolomide
Female0
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SGT-53 With Temozolomide
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)SGT-53 With Temozolomide
Taiwan1
Number of Relapse
Number of Relapse(Participants)SGT-53 With Temozolomide
First1
Second0
Third0
08

Study locations

2 sites
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • China Medical University Hospital
    Taichung, 40447, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Nov 2018 and a completion of Nov 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2014
First posted
Jan 16, 2015
Start
Dec 2014
Primary completionActual
Nov 2018
CompletionActual
Nov 2018
Results first posted
Mar 3, 2021
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02340156
Lead sponsor
SynerGene Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 16, 2015
Start date
Dec 2014
Primary completion
Nov 2018
Completion
Nov 2018
Results posted
Mar 3, 2021
Last update
Mar 3, 2021

Study contacts

John deGroot, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion